ArticleGastroenterology & hepatology2011
New Developments in Traveler's Diarrhea.
Article in Gastroenterology & hepatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 68 citations in OpenAlex.
- Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.Clinical and vaccine immunology : CVI · 2016Trial
- Health benefits and value addition of bovine colostrum (BC): a comprehensive review of its nutritional and functional potential.Food science of animal resources · 2026Review
- Molecular and Genetic Characterization ofMicroorganisms · 2025Article
- Norovirus acute gastroenteritis amongst US and European travellers to areas of moderate to high risk of travellers' diarrhoea: a prospective cohort study.Journal of travel medicine · 2024Observational
- Article
- Assessment of diagnosis and treatment practices of diarrhoea in children under five in Maputo-Mozambique.International journal of Africa nursing sciences · 2022Article
- A comprehensive and high-quality collection ofMicrobial genomics · 2021Article
- Bovine Colostrum and Its Potential for Human Health and Nutrition.Frontiers in nutrition · 2021Review
- Enteric etiological surveillance in acute diarrhea stool of United States Military Personnel on deployment in Thailand, 2013-2017.Gut pathogens · 2020Article
- Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.Vaccine · 2019Review
- The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.Annals of the New York Academy of Sciences · 2019Review
- A Historical Review on Antibiotic Resistance of FoodborneFrontiers in microbiology · 2019Review
- Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a prospective cohort study protocol.BMC infectious diseases · 2018Article
- Development of Molecular Diagnosis Using Multiplex Real-Time PCR and T4 Phage Internal Control to Simultaneously Detect Cryptosporidium parvum, Giardia lamblia, and Cyclospora cayetanensis from Human Stool Samples.The Korean journal of parasitology · 2018Article
- Antibiotic treatment of acute gastroenteritis in children.F1000Research · 2018Review
- Antimicrobial resistance acquisition after international travel in U.S. travelers.Tropical diseases, travel medicine and vaccines · 2016Article
- Tropical and travel-associated norovirus: current concepts.Current opinion in infectious diseases · 2015Review
- A review approaches to identify enteric bacterial pathogens.Jundishapur journal of microbiology · 2015Review
- Combination vaccines against diarrheal diseases.Human vaccines & immunotherapeutics · 2015Review
- Characterization of the human gut microbiome during travelers' diarrhea.Gut microbes · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traveler's diarrhea (TD) is a crucial area for research, as it affects millions of tourists each year and creates a large economic burden. More than 60% of TD cases are caused by a variety of bacterial enteropathogens: diarrhea-producing Escherichia coli, Shigella, Campylobacter, Salmonella, Aeromonas, Plesiomonas, and noncholera Vibrios. Noroviruses are also an important cause of morbidity among travelers. Recent studies have identified host genetic risk factors associated with susceptibility to pathogen-specific TD. Prevention strategies should be emphasized, as all individuals with TD experience approximately 24 hours of disability and 5-10% experience chronic functional bowel disease. Poorly absorbed rifaximin provides protection for trips lasting 2 weeks or less. TD vaccines are also currently in development. All individuals planning trips to developing regions should be armed with 1 of the 3 agents that have shown efficacy for self-treatment of TD: ciprofloxacin (or levofloxacin), rifaximin, or azithromycin, depending upon the location of the trip. Although global epidemiologic changes in etiologic agents as well as antibiotic resistance patterns have been better understood recently, changes should be expected during the next decade due to new prevention and treatment approaches.
Indexed as
Identifiers
21475415PMC3061023W2166507812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.